Troxacitabine: BCH 4556, SPD 758, Troxatyl

Drugs in R and D

Volumn 4, Issue 4, 2003, Pages 264-268

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; DOXORUBICIN; IDARUBICIN; NUCLEOSIDE ANALOG; PACLITAXEL; SPD 758; STEROID; TROXACITABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; AGRANULOCYTOSIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLAST CELL; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL TUMOR; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG TOLERABILITY; DRY SKIN; FATIGUE; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY TUMOR; LUNG NON SMALL CELL CANCER; MELANOMA; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; NORTH AMERICA; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE TUMOR; RASH; SKIN DISEASE; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0041633676     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200304040-00010     Document Type: Article

References (18)

1. Stephenson Jr J, Baker SD, Aylesworth C. A phase I safety and pharmacokinetic study of BCH-4556, a novel L-nucleoside antimetabolite, on a daily × 5 day every 21-day schedule in patients with solid neoplasms. Annals of Oncology 9 (Suppl. 2): 156, 1998
2. Bélanger K, Moore M, Siu L. A phase I study of the L-nucleoside analogue B-L-dioxolane-cytidine (BCH-4556) given as a 30 minute infusion every 21 days. 35th Annual Meeting of the American Society of Clinical Oncology 18: 197, 15 May 1999
3. Canova A, Yee L, Baker S. A phase I and pharmacokinetic study of beta-L-dioxalo-cytidine (BCH-4556) administered weekly for three weeks every 28 days. 35th Annual Meeting of the American Society of Clinical Oncology 18: 197, 15 May 1999
4. Baker SD, Stephenson J, Goetz A. Determinants affecting beta-L-dioxolane-cytidine (BCH-4556) exposure and relationship with toxicity in phase I trials. 35th Annual Meeting of the American Society of Clinical Oncology 18: 197, 15 May 1999
5. Stephenson J, Baker SD, Simmons C, et al. Phase I and pharmacokinetic study of troxacitabine (b-L-dioxolan-cytidine; BCH-4556) on a daily × 5 day every 4-week schedule. European Journal of Cancer 35 (Suppl. 4): 284, Sep 1999
6. Moore M, Belanger K, Jolivet J, et al. NCIC CTG IND 103: a phase I and pharmacokinetic study of the novel L-nucleoside analog troxacitabine (BCH-4556) given every 21 days. European Journal of Cancer 35 (Suppl. 4): 284, Sep 1999
7. Moore M, Belanger K, Dionne J, et al. Troxacitabine (BCH-4556), a nucleoside analog with distinct stereochemical, pharmacologic and pharmacokinetic characteristics is tolerable and active in phase I studies: the NIC-C CTG experience. Clinical Cancer Research 5 (Suppl.): 3729, Nov 1999
8. BioChem Pharma Inc. BioChem, Pharma Inc - new studies to evaluate troxatyl (TM) in leukemia patients. Media Release: [4 pages], 4 Dec 2000. Available from: URL: http://www.biochem-pharma.com
9. Giles F, Belanger R, Toor A, et al. A phase I/II multi-center study of Troxatyl TM in patients with refractory chronic lymphocytic leukemia, lymphoma or multiple myeloma. Blood 98: 289, Part 2, 16 Nov 2001
10. Kadhim S, Waud W, Angers E. BCH-4556: a novel nucleoside analog with potent in vivo activity against renal cancer. 88th Annual Meeting of the American Association for Cancer Research: 99-100, 12 Apr 1997
11. Bowlin T, Genne P, Kadhim S. A novel cytidine nucleoside analogue, BCH-4556, with potent activity against human anthracycline-resistant leukaemia. 88th Annual Meeting of the American Association for Cancer Research: 100, 12 Apr 1997
12. Rabbani SA, Harakidas P, Bowlin T. Prevention of prostate cancer progression and metastasis by a novel nucleoside analogue. 88th Annual Meeting of the American Association for Cancer Research: 100, 12 Apr 1997
13. Attardo G, Kadhim, S, Angers E. Dose scheduling effects on the antitumor activity of BCH-4556 against human tumor xenografts in nude mice. 88th Annual Meeting of the American Association for Cancer Research: 100, 12 Apr 1997
14. Roeltgen D, Ross J. Role of estrogen deficiency in cognitive function of women and premature ovarian failure. Neurology 56 (Suppl. 3): 52, 2001
15. Kadhim SA, Bowlin TL, Waud WR, et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Research 57: 4803-4810, 1 Nov 1997
16. Rabbani SA, Harakidas P, Bowlin T, et al. Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Research 58: 3461-3465, 1 Aug 1998
17. Giles FJ, Garcia-Manero G, Cortes JE, et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. Journal of Clinical Oncology 20: 656-664, 1 Feb 2002
18. Dent SF, Arnold A, Stewart D, et al. NCIC CTG IND 120: phase II study of troxacitabine in patients with advanced non-small cell lung cancer. 37th Annual Meeting of the American Society of Clinical Oncology 20: 259, Part 2, 12 May 2001